MLSS vs SYK vs HSIC vs BDX vs ZBH

For growth investors, Stryker Corporation (SYK) is the stronger pick with 11.

2% revenue growth year-over-year, versus -12. 2% for Milestone Scientific Inc. (MLSS). Henry Schein, Inc. (HSIC) offers the better valuation at 21. 7x trailing P/E (13. 2x forward), making it the more compelling value choice. Analysts rate Stryker Corporation (SYK) a "Buy" — based on 50 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Henry Schein, Inc.

(HSIC) is the cheapest at 21. 7x versus Stryker Corporation at 34. 0x. On forward P/E, Zimmer Biomet Holdings, Inc. is actually cheaper at 9. 7x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Becton, Dickinson and Company wins at 0. 72x versus Henry Schein, Inc. 's 4. 20x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Stryker Corporation (SYK) delivered a total return of +17.

5%, compared to -80. 6% for Milestone Scientific Inc. (MLSS). Over 10 years, the gap is even starker: SYK returned +179. 2% versus MLSS's -80. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Stryker Corporation (SYK) is the lower-risk stock at 0.

52β versus Milestone Scientific Inc. 's 0. 85β — meaning MLSS is approximately 62% more volatile than SYK relative to the S&P 500. On balance sheet safety, Milestone Scientific Inc. (MLSS) carries a lower debt/equity ratio of 6% versus 77% for Henry Schein, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Stryker Corporation (SYK) is pulling ahead at 11.

2% versus -12. 2% for Milestone Scientific Inc. (MLSS). On earnings-per-share growth, the picture is similar: Milestone Scientific Inc. grew EPS 37. 9% year-over-year, compared to -19. 9% for Zimmer Biomet Holdings, Inc.. Over a 3-year CAGR, SYK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Stryker Corporation (SYK) is the more profitable company, earning 12.

9% net margin versus -54. 6% for Milestone Scientific Inc. — meaning it keeps 12. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: SYK leads at 19. 5% versus -78. 3% for MLSS. At the gross margin level — before operating expenses — MLSS leads at 74. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Becton, Dickinson and Company (BDX) is the more undervalued stock at a PEG of 0. 72x versus Henry Schein, Inc. 's 4. 20x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Zimmer Biomet Holdings, Inc. (ZBH) trades at 9. 7x forward P/E versus 19. 1x for Stryker Corporation — 9. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for SYK: 36. 5% to $389. 62.

In this comparison, BDX (2.

8% yield), SYK (1. 2% yield), ZBH (1. 2% yield) pay a dividend. MLSS, HSIC do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Stryker Corporation (SYK) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

52), 1. 2% yield, +179. 2% 10Y return). Both have compounded well over 10 years (SYK: +179. 2%, MLSS: -80. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

SYK, BDX, ZBH pay a dividend while MLSS, HSIC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.